Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Peter Gregos
Observed names:
P. Gregos,
Peter S Gregos,
Peter S. Gregos
Institutions:
NewYork–Presbyterian Hospital,
NewYork–Presbyterian Brooklyn Methodist Hospital,
Weill Cornell Medicine
Observed institutions:
NewYork–Presbyterian Hospital,
NewYork–Presbyterian Brooklyn Methodist Hospital,
Weill Cornell Medicine
ORCID:
0009-0009-7142-8091
Observed ORCID:
0009-0009-7142-8091
OpenAlex ID:
A5089851619
Role of Immune Checkpoint Inhibitors in Gastrointestinal Malignancies
2020
·
Anita Mazloom
, Nima Ghalehsari
, et al.
·
Journal of Clinical Medicine
·
24
PDF
A phase I/II dose-escalation study of fractionated 225Ac-J591 for progressive metastatic castration-resistant prostate cancer (mCRPC) in patients with prior treatment with 177Lu-PSMA.
2023
·
Jones T. Nauseef
, Michael Philip Sun
, et al.
·
Journal of Clinical Oncology
·
14
Outcomes in COVID-19 Patients on Treatment Dose Anti-Coagulation Compared to Prophylactic Dose Anti-Coagulation
2020
·
Rich Kodama
, Amardeep Kalsi
, et al.
·
Blood
·
12
PDF
Phase I/II trial of pembrolizumab and AR signaling inhibitor +/- 225Ac-J591 for chemo-naive metastatic castration-resistant prostate cancer (mCRPC).
2022
·
Scott T. Tagawa
, Joseph Osborne
, et al.
·
Journal of Clinical Oncology
·
9
Phase I/II study of 225Ac-J591 plus 177Lu-PSMA-I&T for progressive metastatic castration-resistant prostate cancer.
2022
·
Jones T. Nauseef
, Joseph Osborne
, et al.
·
Journal of Clinical Oncology
·
7
Abstract CT014: Phase I dose-escalation study of fractionated dose 225Ac J591 for metastatic castration resistant prostate cancer
2023
·
Jones T. Nauseef
, Michael Sun
, et al.
·
Cancer Research
·
6
1606P Mature follow up of phase I dose finding trial of pembrolizumab (pembro) with AR inhibitors (ARI) and priming tumour-targeted radiation with anti-PSMA alpha emitter 225Ac-J591
2024
·
A. Holmes
, C. Thomas
, et al.
·
Annals of Oncology
·
4
PDF
High Dose Cyclophosphamide for the Treatment of Severe Immune Checkpoint Inhibitor Related Adverse Events
2023
·
Timothy Davis
, Kateryna Fedorov
, et al.
·
Journal of Oncology Research and Therapy
·
3
PDF
A Phase I Dose-Escalation/Expansion Study of Fractionated-Dose and Multiple-Cycle Anti–PSMA-Targeted α-Emitter 225Ac-J591 in Patients with Prostate Cancer
2026
·
Scott T. Tagawa
, Charlene Thomas
, et al.
·
Clinical Cancer Research
·
2
PDF
Self-reported race and zip code by men with prostate cancer in New York City and association with access to PSMA PET scans.
2022
·
Jones T. Nauseef
, Juana Martinez Zuloaga
, et al.
·
Journal of Clinical Oncology
·
1
PDF
ABO Blood Type and Outcomes in a Diverse COVID-19 Infected Population
2020
·
Sonal Paul
, Nisha Patel
, et al.
·
Blood
·
1
PDF
COVID-19 Prognostic Score Utilizing Hematological and Inflammatory Markers to Determine Outcomes of Hospitalized Patients
2020
·
Amardeep Kalsi
, Sana Irfan Khan
, et al.
·
Blood
·
1
PDF
Evaluation of Antiplatelet and Anticoagulation Therapy in High-Risk COVID-19 Patients
2020
·
Farah Ashraf
, Anita Mazloom
, et al.
·
Blood
·
1
PDF
Supplementary Figure S2 from A Phase I Dose-Escalation/Expansion Study of Fractionated-Dose and Multiple-Cycle Anti–PSMA-Targeted α-Emitter 225Ac-J591 in Patients with Prostate Cancer
2026
·
Scott T. Tagawa
, Charlene Thomas
, et al.
Supplementary Methods S1 from A Phase I Dose-Escalation/Expansion Study of Fractionated-Dose and Multiple-Cycle Anti–PSMA-Targeted α-Emitter 225Ac-J591 in Patients with Prostate Cancer
2026
·
Scott T. Tagawa
, Charlene Thomas
, et al.
Supplementary Table S7 from A Phase I Dose-Escalation/Expansion Study of Fractionated-Dose and Multiple-Cycle Anti–PSMA-Targeted α-Emitter 225Ac-J591 in Patients with Prostate Cancer
2026
·
Scott T. Tagawa
, Charlene Thomas
, et al.
Data from A Phase I Dose-Escalation/Expansion Study of Fractionated-Dose and Multiple-Cycle Anti–PSMA-Targeted α-Emitter 225Ac-J591 in Patients with Prostate Cancer
2026
·
Scott T. Tagawa
, Charlene Thomas
, et al.
Supplementary Figure S4 from A Phase I Dose-Escalation/Expansion Study of Fractionated-Dose and Multiple-Cycle Anti–PSMA-Targeted α-Emitter 225Ac-J591 in Patients with Prostate Cancer
2026
·
Scott T. Tagawa
, Charlene Thomas
, et al.
Supplementary Table S4 from A Phase I Dose-Escalation/Expansion Study of Fractionated-Dose and Multiple-Cycle Anti–PSMA-Targeted α-Emitter 225Ac-J591 in Patients with Prostate Cancer
2026
·
Scott T. Tagawa
, Charlene Thomas
, et al.
Supplementary Table S2 from A Phase I Dose-Escalation/Expansion Study of Fractionated-Dose and Multiple-Cycle Anti–PSMA-Targeted α-Emitter 225Ac-J591 in Patients with Prostate Cancer
2026
·
Scott T. Tagawa
, Charlene Thomas
, et al.
Supplementary Table S1 from A Phase I Dose-Escalation/Expansion Study of Fractionated-Dose and Multiple-Cycle Anti–PSMA-Targeted α-Emitter 225Ac-J591 in Patients with Prostate Cancer
2026
·
Scott T. Tagawa
, Charlene Thomas
, et al.
Supplementary Table S6 from A Phase I Dose-Escalation/Expansion Study of Fractionated-Dose and Multiple-Cycle Anti–PSMA-Targeted α-Emitter 225Ac-J591 in Patients with Prostate Cancer
2026
·
Scott T. Tagawa
, Charlene Thomas
, et al.
Supplementary Table S3 from A Phase I Dose-Escalation/Expansion Study of Fractionated-Dose and Multiple-Cycle Anti–PSMA-Targeted α-Emitter 225Ac-J591 in Patients with Prostate Cancer
2026
·
Scott T. Tagawa
, Charlene Thomas
, et al.
Supplementary Figure S1 from A Phase I Dose-Escalation/Expansion Study of Fractionated-Dose and Multiple-Cycle Anti–PSMA-Targeted α-Emitter 225Ac-J591 in Patients with Prostate Cancer
2026
·
Scott T. Tagawa
, Charlene Thomas
, et al.
Supplementary Table S5 from A Phase I Dose-Escalation/Expansion Study of Fractionated-Dose and Multiple-Cycle Anti–PSMA-Targeted α-Emitter 225Ac-J591 in Patients with Prostate Cancer
2026
·
Scott T. Tagawa
, Charlene Thomas
, et al.
Show more works
View as search
Works count:
27
Citation count:
85
H-index:
6
I10-index:
3
Year
Topic
Type